TR199801954T2 - Eprosartan dihidrat ve üretimi ve formülasyonu için bir proses. - Google Patents

Eprosartan dihidrat ve üretimi ve formülasyonu için bir proses.

Info

Publication number
TR199801954T2
TR199801954T2 TR1998/01954T TR9801954T TR199801954T2 TR 199801954 T2 TR199801954 T2 TR 199801954T2 TR 1998/01954 T TR1998/01954 T TR 1998/01954T TR 9801954 T TR9801954 T TR 9801954T TR 199801954 T2 TR199801954 T2 TR 199801954T2
Authority
TR
Turkey
Prior art keywords
formulation
manufacture
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
TR1998/01954T
Other languages
English (en)
Inventor
R. Palepu Nageswara
M. Venkatesh Gopadi
Duddu Sarma
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199801954(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR199801954T2 publication Critical patent/TR199801954T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu bulus,
TR1998/01954T 1996-03-29 1997-03-26 Eprosartan dihidrat ve üretimi ve formülasyonu için bir proses. TR199801954T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
TR199801954T2 true TR199801954T2 (tr) 1998-12-21

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01954T TR199801954T2 (tr) 1996-03-29 1997-03-26 Eprosartan dihidrat ve üretimi ve formülasyonu için bir proses.

Country Status (36)

Country Link
EP (1) EP0889880B1 (tr)
JP (1) JP4316013B2 (tr)
CN (2) CN1214682A (tr)
AP (1) AP901A (tr)
AR (1) AR006439A1 (tr)
AT (1) ATE239723T1 (tr)
AU (1) AU726694B2 (tr)
BG (1) BG64095B1 (tr)
BR (1) BR9708336A (tr)
CA (1) CA2250395C (tr)
CZ (1) CZ293345B6 (tr)
DE (1) DE69721749T2 (tr)
DK (1) DK0889880T3 (tr)
DZ (1) DZ2199A1 (tr)
EA (1) EA001958B1 (tr)
EG (1) EG23889A (tr)
ES (1) ES2198564T3 (tr)
HK (1) HK1016594A1 (tr)
HU (1) HU228263B1 (tr)
ID (1) ID16507A (tr)
IL (1) IL126319A0 (tr)
MA (1) MA24437A1 (tr)
MY (1) MY117682A (tr)
NO (2) NO311760B1 (tr)
NZ (1) NZ332008A (tr)
OA (1) OA11176A (tr)
PL (1) PL188816B1 (tr)
PT (1) PT889880E (tr)
RO (1) RO118870B1 (tr)
SK (1) SK282346B6 (tr)
TR (1) TR199801954T2 (tr)
TW (1) TW434239B (tr)
UA (1) UA49880C2 (tr)
UY (1) UY24504A1 (tr)
WO (1) WO1997036874A1 (tr)
ZA (1) ZA972686B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262102B1 (en) * 1997-06-27 2001-07-17 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
AU2745199A (en) 1998-03-04 1999-09-20 Takeda Chemical Industries Ltd. Sustained-release preparation for aii antagonist, production and use thereof
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
IL140905A0 (en) * 1998-07-20 2002-02-10 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
AU774799B2 (en) * 1999-04-28 2004-07-08 Takeda Pharmaceutical Company Limited Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
HUP0400475A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CN1662256A (zh) * 2002-05-17 2005-08-31 诺瓦提斯公司 用于心肌梗死二级预防的血管紧张素Ⅱ受体阻断剂和β－阻断剂的组合
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
RS20050590A (en) 2003-01-31 2007-09-21 Sankyo Company Limited, Medicine for prevention of and treatment for arteriosclerosis and hypertension
US8361507B2 (en) 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
WO1992010189A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
TW434239B (en) 2001-05-16
ATE239723T1 (de) 2003-05-15
BG102822A (en) 1999-11-30
NO984503L (no) 1998-09-28
EP0889880A1 (en) 1999-01-13
CN1214682A (zh) 1999-04-21
EP0889880B1 (en) 2003-05-07
WO1997036874A1 (en) 1997-10-09
UA49880C2 (uk) 2002-10-15
MA24437A1 (fr) 1998-10-01
RO118870B1 (ro) 2003-12-30
ES2198564T3 (es) 2004-02-01
EP0889880A4 (en) 1999-06-23
HK1016594A1 (en) 1999-11-05
CA2250395C (en) 2005-09-06
ZA972686B (en) 1997-09-29
NO311760B1 (no) 2002-01-21
EG23889A (en) 2007-12-12
UY24504A1 (es) 1997-09-19
AP9700956A0 (en) 1997-04-30
BR9708336A (pt) 1999-08-03
HU228263B1 (en) 2013-02-28
DE69721749D1 (de) 2003-06-12
AU726694B2 (en) 2000-11-16
HUP9902769A2 (hu) 2000-03-28
NZ332008A (en) 1999-05-28
NO2002005I1 (no) 2002-09-02
HUP9902769A3 (en) 2000-04-28
EA199800873A1 (ru) 1999-02-25
SK282346B6 (sk) 2002-01-07
OA11176A (en) 2003-05-13
EA001958B1 (ru) 2001-10-22
CZ293345B6 (cs) 2004-04-14
AR006439A1 (es) 1999-08-25
SK132298A3 (en) 1999-03-12
CA2250395A1 (en) 1997-10-09
JP4316013B2 (ja) 2009-08-19
ID16507A (id) 1997-10-02
AU2547097A (en) 1997-10-22
CN1332167A (zh) 2002-01-23
MY117682A (en) 2004-07-31
DZ2199A1 (fr) 2002-12-03
CZ310198A3 (cs) 1999-03-17
NO984503D0 (no) 1998-09-28
AP901A (en) 2000-11-23
PL329046A1 (en) 1999-03-01
BG64095B1 (bg) 2003-12-31
IL126319A0 (en) 1999-05-09
DK0889880T3 (da) 2003-09-01
PT889880E (pt) 2003-09-30
JP2000508632A (ja) 2000-07-11
DE69721749T2 (de) 2004-03-25
PL188816B1 (pl) 2005-04-29

Similar Documents

Publication Publication Date Title
TR199801954T2 (tr) Eprosartan dihidrat ve üretimi ve formülasyonu için bir proses.
TR199900639T2 (tr) Olanzapin dihidrat D.
DE69708120D1 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
NL1007590A1 (nl) Hydroxyfenyltriazinen.
BR9913221B1 (pt) composiÇço catalisadora suportada de metaloceno.
NL1007031A1 (nl) Hydroxyfenyltriazinen.
ATE180776T1 (de) Naphthylverbindungen, zwischenprodukte, zusammensetzungen und methoden
ATE264863T1 (de) 28-epirapaloge
IS5888A (is) Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni
TR199900651T2 (tr) Kaplanmis parçacik formülasyonu.
ES2191830T3 (es) Inhibidores de trombina.
DE60120712D1 (en) Kallikrein gen
PT1135429E (pt) Poliadicoes em mini-emulsoes aquosas e nao aquosas
TR199802557A3 (tr) Bir offenend-büküm makinesinin isletilmesi amaciyla islem ve düzenek.
ID22228A (id) Turunan-turunan 16-hidroksi-11-(disubstitusifenil)-estra-4,9-diena
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
BR9912037B1 (pt) composições organometálicas.
ES2186807T3 (es) Inhibidores de trombina.
TR199901935T2 (tr) Eprosartan hazirlamak için proses.
DE69623788D1 (de) Herstellungsverfahren für einen Gegenstand
TR199901936T2 (tr) Eprosartan hazirlamak için proses.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
BR9801985B1 (pt) composiÇço farmacÊutica de uso tàpico e respectivo processo de obtenÇço.
ID27316A (id) Proses untuk membuat urea 1,3-terdisubstitusi-4-oksosiklik
NL1008000A1 (nl) Inspectie-jig.